Regranex gel, a new biotech drug for diabetic foot ulcers

    Ortho-McNeil is now marketing Regranex gel, a new biotech drug for diabetic foot ulcers.

    It contains becaplermin...a platelet-derived growth factor to stimulate the growth of new tissue. It's also being tested for nondiabetic ulcers and pressure sores.

    The gel is applied once a day...for up to 20 weeks.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote